This activity is expired and is no longer available for CME credit.


Updates in Melanoma 2015: Entering a New Therapeutic Era

Updates in Melanoma 2015: Entering a New Therapeutic Era

This activity is supported by an educational grant from Merck & Co., Inc.


Author(s)/Faculty: Alain Algazi, MD; Robert H. I. Andtbacka, MD, CM, FACS, FRCSC; Michael B. Atkins, MD; Paul B. Chapman, MD; Keith T. Flaherty, MD; Allan C. Halpern, MD, MSc; Omid Hamid, MD; Axel Hauschild, MD; Steven J. O’Day, MD; Michael Postow, MD; Vernon K. Sondak, MD; Mario Sznol, MD
Source: Healio - Hematology/Oncology Education Lab
Type: MonographArticles/Items: 7
Release Date: 8/1/2015Expiration Date: 8/1/2016
Credit Type: CMENumber of Credits: 1.25
Cost: FreeProvider: Vindico Medical Education
The incidence of melanoma, an aggressive disease that accounts for approximately 75% of skin-cancer-related deaths, is continuing to increase worldwide. Historically, treatment options for patients with advanced-stage melanoma have been limited by modest response rates and failure to improve overall survival (typically less than 1 year). However, in recent years, the treatment landscape for metastatic melanoma was revolutionized with the approval of novel targeted therapies and immunotherapies that showed improved overall survival in Phase 3 clinical trials. Understanding the safety/efficacy profiles of these therapies as well as the optimal strategies for their utilization is critical for physicians. In this program, leading experts in melanoma will discuss the safety and efficacy of recently approved therapies for the treatment of metastatic melanoma, strategies for combining and sequencing these agents, as well as future therapeutic approaches for the treatment of this disease.

CME Information

page 1 of 9